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Abstract For reconstruction or repair of damaged tissues, an
artificially regulated switch from proliferation to differentiation
would be of great advantage. To achieve conditional myogenesis,
we expressed MyoD in mouse C3H 10T1/2 fibroblastic cells,
using a gene regulation system based on the synthetic steroid
RU 486. By stable co-transfection of a plasmid construct with
the RU 486 dependent activator and an integrating inducible
MyoD construct, a cell clone, designated 10T-RM, was obtained
in which MyoD expression was stringently controlled by RU
486. 12 h after addition of 10 nM RU 486 to 10T-RM cells,
saturation levels of MyoD mRNA were observed and v2 days
later, mRNA for embryonal myosin heavy chain (MyHCemb) was
abundant and mononucleated cells fused into myotubes.
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1. Introduction
A hallmark in the formation of skeletal muscle during de-
velopment is cell fate determination of mesenchymal cells and
di¡erentiation of myocytes to multinucleated myotubes by
myogenic transcription factors. These comprise MyoD [1],
myogenin [2^4], Myf-5 [5] and MRF4, also called Myf-6 or
herculin [6^8]. Myogenic transcription factors are basic helix-
loop-helix (bHLH) proteins. They are expressed at di¡erent
times during skeletal muscle development [9^11] and serve
di¡erent steps in muscle di¡erentiation [12,13]. MyoD has
originally been de¢ned by its ability to convert cultured ¢bro-
blasts (C310T1/2 [14]) into a myogenic phenotype [1,15].
Reconstructing muscle is a major concern in the treatment
of muscle diseases which result in a reduction of muscle mass.
In mouse models many attempts have been made to reconsti-
tute muscle tissue or to replace muscle ¢bres by the implan-
tation of primary myoblasts or myogenic cell lines like C2C12
[16^19]. However cell therapy trials on patients su¡ering from
Duchenne muscular dystrophy (DMD) with myoblasts have
not been successful so far due to the low proliferation capacity
of implanted myogenic cells [20,21]. An alternative approach
could be a treatment based on the genetic conversion of ex
vivo engineered ¢broblasts involving compensation of the dys-
trophin de¢ciency and ¢broblast-myoblast conversion by
myogenic factors.
An inducible expression of myogenic factors would allow
for a control of proliferation versus myogenic di¡erentiation
in cell culture and presumably in the organism, provided that
control of myogenic factor expression is not leaky. A variety
of regulatory systems are available in which conditional ex-
pression is achieved by non-toxic ligands like tetracycline (tet)
or by steroids. The tet-system is based on the bacterial tet
repressor (tetR) whose ligand dependent DNA binding mod-
ule has been fused to a transactivator VP 16 from Herpes
simplex virus to act as a repressor, tTA [22] or as an activator,
rtTA, which contains a mutated tet repressor [23]. In conjunc-
tion with a target promoter containing tet operator sites, tran-
scription is either repressed (tTA) or induced (rtTA) by tet.
Alternatively, steroid based inducible systems make use of
ligand binding domains of steroid hormone receptors either
from other species that bind ecdysone [24] or from mutated
ligand binding domains with high a⁄nity to antihormones
tamoxifen [25] or antiprogesterone RU 486 [26^29]. In the
latter case, the RU 486 dependent transactivator contains
the progesterone binding domain of the human progesterone
receptor (PR) with a 42 amino acid deletion in its C-terminus.
This truncated domain binds only the progesterone antagonist
RU 486 with high a⁄nity [30] ; when fused to a GAL4-DNA
binding domain and to a VP16 transactivator, it mediates RU
486 dependent binding of the regulator to a target promoter
containing multiple GAL4 binding sites. To circumvent po-
tential enhancer e¡ects due to integration of the chimaeric
regulator and the target promoter, an episomal construct
based on Epstein-Barr virus (EBV) is introduced in host cells,
leading to high level expression of the RU 486 dependent
transactivator (see Fig. 1a; [26]). The present study was ini-
tiated to explore the suitability of an RU 486 inducible system
for conditional MyoD expression in 10T1/2 ¢broblasts with
the aim to control myogenesis in culture with the ¢nal aim to
reconstruct muscle in experimental animals.
2. Materials and methods
2.1. Vector construction
The cDNA for MyoD ([1]; gift of E.-M. Fu«chtbauer, Freiburg,
Germany) was cloned in pSBC-2 [31]; gift of H. Hauser, Braun-
schweig, Germany) as an EcoRI fragment. For construction of an
RU 486 inducible MyoD target vector, the SV 40 promoter fragment
of pSBC2-MyoD was cleaved by ClaI, ¢lled-in with Klenow DNA
polymerase, and digested with XhoI. The RU 486 target promoter
p17x4-tk containing four copies of GAL4 consensus sequence linked
to the thymidine kinase (tk) gene promoter [26], was digested by
HindIII, ¢lled-in, redigested with XhoI and ligated into the respective
sites of pSBC2-MyoD. This construct is designated pSBC2-tk-MyoD.
To allow for selection of 10T1/2 cell clones using G418, we cloned the
chimaeric regulator hPRB891/GAL4/VP16 (GL-VP) by BamHI and
KpnI digestion and ligation into the respective sites of pCEP9 (In-
vitrogen, Groningen, Netherlands) to yield GL-VPneo.
2.2. Cell culture and transfections
C3H 10T1/2 ¢broblast cells (subline CCL-226) were obtained
from ATCC (Rockville, MD, USA) and cultured under 5% CO2 in
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Dulbecco’s modi¢ed Eagle medium (DMEM) containing 10% (v/v)
foetal calf serum (FCS). 10T1/2 cells of low passage numbers (95)
were frozen in aliquots. For transfection, usually 1.5U105 cells were
seeded into 60 mm plates and vector constructs were added 24 h later
for 6 h along with Transfectam (Promega, Madison, WI, USA) in
serum-free medium. Usually, cotransfections were done in ratios of
1:5, 1:10, and 1:20 of GL-VPneo to pSBC2-GAL4-MyoD. 2 days
after transfection, transfectants were selected with 400 Wg/ml G418
(Gibco BRL). For fusion experiments, 10T-RM or control C2C12
cells were seeded onto collagenised cover slips and kept in DMEM
containing 5% FCS or 2% horse serum (HS), respectively. In addition,
along with changing to di¡erentiation medium, the solvent ethanol
alone or RU 486 in ethanol was added.
2.3. Quanti¢cation of chloramphenicol acetyltransferase (CAT)
The amount of CAT protein was determined using the enzyme
linked immunosorbent assay (ELISA) system supplied by Boehringer
(Ingelheim, Germany). Cell cultures were washed twice with phos-
phate bu¡ered saline and lysed by addition of 1 ml lysis bu¡er sup-
plied by the manufacturer. The colourimetric assay yields the concen-
tration of CAT protein in ng/mg protein by reference to a standard
curve.
2.4. Isolation of RNA and Northern blot analysis
Total RNA from cultured cells was isolated by the RNeasy prepa-
ration method (Qiagen, Hilden, Germany). For each sample, 10 Wg of
total RNA was fractionated by electrophoresis on a 1% agarose form-
aldehyde gel and transferred in 20U standard saline citrate bu¡er
(SSC) to nylon membranes (Pall Biodyne B, Pall, Dreieich, Germany).
The blots were subsequently hybridised with [K-32P]dATP random
prime labelled EcoRI fragments of MyoD cDNA or an 18S rRNA
DNA fragment, respectively.
2.5. RT-PCR analysis
1 Wg of total RNA in 20 Wl reaction volume was subjected to reverse
transcription (RT) using SuperScript reverse transcriptase (Life Tech-
nologies GmbH, Eggenstein, Germany). After RT, 5 Wl of this mixture
were used for PCR ampli¢cation in a total volume of 50Wl containing
10 pmol of each primer and 1 Unit of AmpliTaq (Perkin-Elmer
GmbH, Uº berlingen, Germany). For embryonic myosin heavy chain,
MyHCemb, the primers were: MYHCs: 5P-GCAAGGAATGCA-
GAGGAGAAGG-3P ; MYHCas: 5P-CCTGCCTCTTGTAGGACTT-
GA-3P [32]; for ribosomal protein L7 mRNA: L7s: 5P-AGATG-
TACCGCACTGAGATTC-3P ; L7as: 5P-ACTTACCAAGAGACCG-
AGCAA-3P [33]. Primers were obtained from TIB MolBiol (Berlin,
Germany). PCR conditions were: 4 min 94‡C, 1 min 64‡C, 1 min
72‡C, 1 min 92‡C for 20^30 cycles. The resulting ampli¢cation prod-
ucts (403 bp for MyHCemb and 352 bp for L7) were separated by
electrophoresis on a 1% agarose gel and visualised with ethidium
bromide.
2.6. Documentation
Photodocumentation on cells grown on collagen coated coverslips
was done on a Zeiss Axiophot microscope with phase contrast mi-
croscopy. Images were processed by Adobe Photoshop, version 5.0.
3. Results
Stable 10T1/2 cell clones expressing constitutively MyoD,
Myogenin, or Myf-4 were generated and analysed for their
di¡erentiation potential. At cell densities of s 60% con£uency
most of the cell clones showed spontaneous di¡erentiation to
multinucleated myotubes, even in proliferation medium. Con-
Fig. 1. Constructs and experimental procedures for the production
of RU 486 inducible 10T1/2 cell clones and regulated myogenesis.
a: Constructs: (1) EBV vector carrying the RU 486 responsive do-
main (‘SBDmut’, ligand binding domain of the human PR
hPRB891), the GAL4 DNA binding domain (‘GAL4DBD’), and
the VP 16 transactivation domain from Herpes simplex (‘VP 16’);
(2) target construct with four GAL4 consensus sequences oriented
in sense, a minimal tk promoter, and CAT gene; (3) the same for
MyoD. b: Steps to produce from 10T1/2 cells the RU 486 depen-
dent CAT expression clone 10T-RC and the corresponding MyoD
expressing clone 10T-RM.
Fig. 2. RU 486 inducibility in 10T1/2 cell clones of the CAT report-
er gene. a: Concentration of CAT protein in 10 representative
10T1/2 cell clones without RU 486 (open columns) or 24 h after ad-
dition of 10 nM RU 486 (hatched columns). b: RU 486 dependent
expression of CAT protein in clone 10T-RC ( = clone #3 of upper
panel). B = Basal value in the absence of RU 486; Mean val-
ues þ S.D. of triplicate experiments.
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stitutive overexpression of myogenic factors in these cell
clones obviously bypasses the requirement for an external
stimulus (e.g. low serum) probably due to a high copy number
of myogenic factor genes present in these cell clones. Conse-
quently, these clones could not be grown to large cell num-
bers.
For controlled myogenesis we used the inducible expression
system based on the synthetic steroid RU 486 as a ligand (Fig.
1; [26]). To test whether this system is feasible in 10T1/2 cells,
we co-transfected the CAT reporter target construct
(ptkCAT) together with the chimaeric regulator and selected
Fig. 4. RU 486 dependent di¡erentiation of 10T-RM cells in culture. a and b: without inducer, subcon£uent (a) or con£uent (b); with inducer
1 day (c), 4 days (d) and 7 days (e) after addition of 10 nM RU 486. f: 7 Days after addition of 1 nM RU 486. Bar in (a) 10 Wm, valid for
whole panel. In d and e, large myotubes are seen; in f, myotubes are less mature.
Fig. 3. RU 486 dependent expression of MyoD (A) and embryonic
myosin heavy chain (B). a: Northern-blot of total RNA from cell
clone 10T-RM, 24 h after addition of ethanol control (0) and vari-
ous concentrations of RU 486. For each lane, 10 Wg total RNA
were applied and after electrophoresis and blotting hybridised
against the probes indicated to the right; MyoD, cDNA probe;
18S, cDNA probe for 18S ribosomal RNA. b: Secondary induction
of myosin heavy chain (embryonal), ‘MyHC’, as determined after
25 cycles RT-PCR. 10T-RM cells, either uninduced or induced with
RU 486 for 2 days; C2C12 cells, undi¡erentiated myoblasts (‘mb’)
or myotubes, 2 days after change to di¡erentiation medium (‘mt’).
‘no RT’, control without RT. Internal standard, RT-PCR for ribo-
somal protein L7 mRNA. The ampli¢cate sizes in bp are given be-
low.
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co-transfected cell clones. Of four representative clones, 10T-
RC (clone #3 in Fig. 2a) showed a basal expression of 0.06 ng
CAT/mg protein in the absence of the inducer and a s 100-
times higher CAT concentration after addition of 10 nM RU
486 (Fig. 2a). The dose response curve showed a half-maximal
induction at 0.2 nM RU 486 and a maximal induction at v10
nM RU 486 (Fig. 2b). After induction with 10 nM RU 486,
more than 90% of 10T-RC cells stained for CAT protein with
a chicken anti-CAT antibody (not shown).
Similarly, we generated 10T1/2 cell clones containing
ptkMyoD and the episomal regulator GL-VP (Fig. 1a). Selec-
tion, however, was di⁄cult : many cell clones already showed
myogenic di¡erentiation in the absence of RU 486, probably
due to a high basal rate of MyoD expression. Another frac-
tion of cell clones did not respond to RU 486, i.e. there was
no induction of MyoD mRNA.
Only one out of 60 clones characterised, designated 10T-
RM, proliferated in the absence of RU 486 and, 24 h after
addition of 10 nM RU 486, showed a s 50-fold induction of
MyoD mRNA as determined by Northern blot analysis (Fig.
3a). MyoD dependent myogenic di¡erentiation was monitored
by mRNA levels for myosin heavy chain (embryonal;
MyHCemb). MyHC speci¢c ampli¢cates of 403 bp size were
only seen in RNA from RU 486 induced 10T-RM cells (Fig.
3b). As a positive control we triggered myogenic di¡erentia-
tion in C2C12 cells by serum withdrawal and determined
mRNA levels for MyHCemb. In the myoblast stage, C2C12
cells did not express MyHCemb mRNA, whereas 1 day after
serum withdrawal the MyHCemb mRNA level was upregu-
lated (Fig. 3b).
Without RU 486, we never observed any morphological
changes in 10T-RM cells which would be indicative for myo-
genic di¡erentiation, independent of the degree of con£uency
(Fig. 4a,b). After addition of 10 nM RU 486, morphological
changes in 10T-RM cells were observed already after 1 day
(Fig. 4c) and di¡erentiation proceeded to myotubes within
7 days (Fig. 4d,e). Myogenic di¡erentiation also occurred
with 1 nM RU 486 (Fig. 4f).
In a total of 25 experiments with 10T-RM cells of di¡erent
passage numbers (4^10) we always observed stringent control
of myotube formation by RU 486.
4. Discussion
Constitutive myogenisation of skin ¢broblasts and their
subsequent participation in muscle ¢bre formation in the
mouse has previously been achieved [34]. Here we demon-
strate the feasibility of a regulated expression of a myogenic
factor leading to conditional myogenesis in cell culture. As a
model cell line we used C310T1/2 ¢broblasts that can be con-
verted into myogenic cells as demonstrated by azacytidine
treatment [1]. Anti-estrogen and glucocorticoid inducible chi-
maeric myogenic factors have been constructed for condition-
al myogenesis of 10T1/2 cells, but no clearcut data on the
regulation in this system have been presented [35,36]. Further-
more these inducers, at the concentrations required, would
interfere with metabolism and immune defence in the organ-
ism.
Our approach to construct RU 486 responsive ¢broblastic
cells has faced some technical di⁄culties : First, a substantial
fraction of 10T1/2 cell clones transfected with target promoter
and regulator failed to respond by MyoD expression in the
presence of the inducer. Second, many other cell clones under-
went premature di¡erentiation presumably due to a high basal
activity of the RU 486 dependent target promoter. For this
reason, a large number of cell clones had to be grown and a
subset of these characterised in order to obtain a cell line
tightly regulated in culture. Under these conditions, myogen-
esis was reproducible and clear-cut and proceeded up to the
myotube stage which approximately corresponds to gestation-
al day 12^16 in the mouse.
Future investigations will have to deal with myogenesis by
10T-RM cells in the environment of the organism and the
possibility to repair muscle damage. These experiments re-
quire an appropriate labelling system to distinguish donor
from host cells [37,38] and long-term immunological toler-
ance. We are presently constructing recipient mice that ful¢l
these conditions.
Acknowledgements: This work was supported by the Deutsche For-
schungsgemeinschaft (Schwerpunktprogramm Muskelforschung) and
the Volkswagen Foundation (I 72/438). Advice by Dr M. Truss and
the kind gift of RU 486 from Dr M. Beato are gratefully acknowl-
edged. We thank Drs E.-M. Fu«chtbauer, T. Braun and H.-H. Arnold
for MyoD and Myf-4 expression plasmids, Dr H. Hauser for the
pSBC-2 plasmid, Drs Bert O’Malley, S. Tsai, and Y. Wang, Baylor
College, Houston for providing plasmids of the RU 486 regulation
system, and for helpful information. The excellent technical assistance
of S. Gehner, A. Becker, and S. Voigt is gratefully acknowledged.
References
[1] Davis, R.L., Weintraub, H. and Lassar, A.B. (1987) Cell 51, 987^
1000.
[2] Braun, T., Bober, E., Buschhausen-Denker, G., Kohtz, S., Grzes-
chik, K.-H. and Arnold, H.-H. (1989) EMBO J. 8, 3617^3625.
[3] Edmondson, D.G. and Olson, E.N. (1989) Genes Dev. 3, 628^
640.
[4] Wright, W.E., Sassoon, D.A. and Lin, V.K. (1989) Cell 56, 607^
617.
[5] Braun, T., Buschhausen-Denker, G., Bober, E., Tannich, E. and
Arnold, H.-H. (1989) EMBO J. 8, 701^709.
[6] Rhodes, S.J. and Konieczny, S.F. (1989) Genes Dev. 3, 2050^
2061.
[7] Braun, T., Bober, E., Winter, B., Rosenthal, N. and Arnold,
H.-H. (1990) EMBO J. 9, 821^831.
[8] Miner, J.H. and Wold, B. (1990) Proc. Natl. Acad. Sci. USA 87,
1089^1093.
[9] Buckingham, M. (1996) Biochem. Soc. Trans. 24, 506^509.
[10] Arnold, H.-H. and Braun, T. (1996) Int. J. Dev. Biol. 40, 345^
353.
[11] Borycki, A.G. and Emerson, C.P. (1997) Curr. Biol. 7, 620^623.
[12] Lassar, A. and Munsterberg, A. (1994) Curr. Opin. Cell. Biol. 6,
432^442.
[13] Buonanno, A. and Rosenthal, N. (1996) Dev. Genet. 19, 95^107.
[14] Rezniko¡, C.A., Brankow, D.W. and Heidelberger, C. (1973)
Cancer Res. 33, 3239^3249.
[15] Lassar, A.B., Paterson, B.M. and Weintraub, H. (1986) Cell 47,
649^656.
[16] Partridge, T.A. (1991) Muscle Nerve 14, 197^212.
[17] Partridge, T.A. and Davies, K.E. (1995) Br. Med. Bull. 51, 123^
137.
[18] Wernig, A., Irintchev, A., Hartling, A., Stephan, G., Zimmer-
mann, K. and Starzinski-Powitz, A. (1991) J. Neurocytol. 20,
982^997.
[19] Wernig, A. and Irintchev, A. (1995) J. Neurol. Sci. 130, 190^196.
[20] Blau, H.M., Pavlath, G.K., Hardeman, E.C., Chiu, C.P., Silber-
stein, L., Webster, S.G., Miller, S.C. and Webster, C. (1985)
Science 230, 758^766.
[21] Webster, C. and Blau, H.M. (1990) Somat. Cell Mol. Genet. 16,
557^565.
[22] Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci. USA
89, 5547^5551.
FEBS 23282 28-1-00
J.W. Bartsch et al./FEBS Letters 467 (2000) 123^127126
[23] Gossen, M., Freundlieb, S., Bender, G., Mu«ller, G., Hillen, W.
and Bujard, H. (1995) Science 268, 1766^1769.
[24] No, D., Yao, T.P. and Evans, R.M. (1996) Proc. Natl. Acad. Sci.
USA 93, 3346^3351.
[25] Sourisseau, T., Le Drean, Y., Salbert, G., Flamant, F. and Mi-
chel, D. (1999) Biotechniques 27, 106^110.
[26] Wang, Y., O’Malley Jr., B., Tsai, S.Y. and O’Malley, B.W.
(1994) Proc. Natl. Acad. Sci. USA 91, 8180^8184.
[27] Wang, Y., DeMayo, F.J., Tsai, S.Y. and O’Malley, B.W. (1997)
Nature Biotechnol. 15, 239^243.
[28] Wang, Y., Xu, J., Pierson, T., O’Malley, B.W. and Tsai, S.Y.
(1997) Gene Ther. 4, 432^441.
[29] Baulieu, E.-E. (1989) Science 245, 1351^1357.
[30] Vegeto, E., Allan, G.F., Schrader, W.T., Tsai, M.J., McDonnell,
D.P. and O’Malley, B.W. (1992) Cell 69, 703^713.
[31] Dirks, W., Wirth, M. and Hauser, H. (1993) Gene 128, 247^249.
[32] Weydert, A., Daubas, P., Lazaridis, I., Barton, P., Garner, I.,
Leader, D.P., Bonhomme, F., Catalan, J., Simon, D. and Gue-
net, J.-L. et al. (1985) Proc. Natl. Acad. Sci. USA 82, 7183^7187.
[33] Krowczynska, A.M., Coutts, M., Makrides, S. and Brawerman,
G. (1989) Nucleic Acids Res. 17, 6408.
[34] Huard, C., Moisset, P.-A., Dicaire, A., Merly, F., Tardif, F.,
Asselin, I. and Tramblay, J.P. (1998) Biochem. Biophys. Res.
Commun. 248, 648^654.
[35] Hollenberg, S.M., Cheng, P.F. and Weintraub, H. (1993) Proc.
Natl. Acad. Sci. USA 90, 8028^8032.
[36] Yagami-Hiromasa, T., Sato, T., Kurisaki, T., Kamijo, K., Nabe-
shima, Y. and Fujisawa-Sehara, A. (1995) Nature 377, 652^656.
[37] Fu«chtbauer, E.M., Reininghaus, J. and Jockusch, H. (1988) Proc.
Natl. Acad. Sci. USA 85, 3880^3884.
[38] Augustin, M., Klopp, N., Ewald, K. and Jockusch, H. (1998)
Cell Biol. Int. 22, 401^411.
FEBS 23282 28-1-00
J.W. Bartsch et al./FEBS Letters 467 (2000) 123^127 127
